NCT01909492View on ClinicalTrials.gov

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

September 20, 2013

Primary Completion Date

October 5, 2023

Study Completion Date

October 5, 2023

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
PROCEDURE

Blood Draw

Patients will provide a serum sample for research.

PROCEDURE

Lumbar Puncture

Patients will have a lumbar puncture to obtain CSF.

Trial Locations (1)

97225

Providence MS Center, Portland

All Listed Sponsors
collaborator

Microstein, LLC

UNKNOWN

lead

Providence Health & Services

OTHER

NCT01909492 - Measurement of Relaxin Peptide in Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter